| James Narrod, MD | |
|
2643 Patterson Rd, Suite 403, Grand Junction, CO 81506-1936 | |
| (970) 298-7675 | |
| (970) 298-1809 |
| Full Name | James Narrod |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery (cardiothoracic Vascular Surgery) |
| Location | 2643 Patterson Rd, Grand Junction, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871570150 | NPI | - | NPPES |
| 01243831 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | DR24383 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| James Narrod, MD 2635 N 7th St, Smmg Cvts, Grand Junction, CO 81501-8209 Ph: (970) 298-2273 | James Narrod, MD 2643 Patterson Rd, Suite 403, Grand Junction, CO 81506-1936 Ph: (970) 298-7675 |
News Archive
Indevus Pharmaceuticals, Inc. has announced that it has entered into a definitive merger agreement under which Endo Pharmaceuticals Holdings, Inc.
With an ever ageing population and more people surviving a heart attack, heart failure is now the world's most prevalent chronic cardiovascular disease.
New research shows that women who undergo ovarian stimulation to produce extra eggs for in-vitro fertilization (IVF) are at increased risk for a type of growth known as "borderline ovarian tumors".
NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of a Phase 3 trial to be used in support of a Biologic License Application (BLA).
vTv Therapeutics LLC today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's Phase 3 placebo controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer's disease.
› Verified 2 days ago
Robert Sean Brooks, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 2373 G Rd Ste 160, Grand Junction, CO 81505 Phone: 970-242-7292 | |
Dr. Leonard Lapkin, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 2643 Patterson Road, Suite 403, Grand Junction, CO 81506 Phone: 970-298-7675 Fax: 970-298-2984 | |
Dr. Danielle Anne Smith, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 2643 Patterson Rd Ste 403, Grand Junction, CO 81506 Phone: 970-298-7675 Fax: 970-298-2984 |